Naʽat

EGFR Tests Market Forecasts to 2033: Comprehensive Analysis of Size, Share, Regulatory Landscape and Global Trends - ResearchAndMarkets.com

Retrieved on: 
Friday, December 22, 2023
Medical Devices, Health, Naʽat, Metastasis, Point mutation, Woman, Afatinib, Country, Male, Smoking, EGFR, SWOT, Apoptosis, Lung cancer, Adenocarcinoma, Cancer, Region, Gefitinib, Market access, Deletion, Tobacco smoking, Patient, Internet, Female, Retail

The "EGFR Tests Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "EGFR Tests Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.
  • The model includes EGFR Immunohistochemistry Tests, EGFR Sanger Sequencing Tests, EGFR Nucleic Acid Amplification Tests (NAATs), and EGFR Other Tests (EGFR ISH and Mass Array tests).
  • Key Inclusions of the market model are:
    Currently marketed EGFR Tests and evolving competitive landscape:
    Insightful review of the key industry trends.
  • Global, Regional and Country level market specific insights:
    Qualitative market specific information is available with global trends further broken down into regional trends.

Global Hepatitis B Tests Market Set for Steady Growth with Increasing Global Awareness and Screening Programs - ResearchAndMarkets.com

Retrieved on: 
Monday, October 16, 2023
General Health, Infectious Diseases, Health, Pharmaceutical, Health Technology, Hepatitis B, Incidence, ASP, Multi, Naʽat, Risk, Pregnancy, WHO, World Health Organization, Vaccination, SWOT analysis, Hepatitis, Tissue, Forecast, Patient, Infection, Vaccine

The global Hepatitis B Tests market is on a trajectory of steady growth, driven by increasing awareness about Hepatitis B, routine screening programs, and the implementation of universal vaccination strategies.

Key Points: 
  • The global Hepatitis B Tests market is on a trajectory of steady growth, driven by increasing awareness about Hepatitis B, routine screening programs, and the implementation of universal vaccination strategies.
  • Donor Screening: Hepatitis B tests are essential for screening donors of human cells, tissues, and cellular and tissue-based products (HCT/P).
  • Diagnostic and Monitoring: Hepatitis B tests are crucial for diagnosing suspected infections, monitoring HBV-positive patients, and assessing the effectiveness of treatment.
  • The Hepatitis B Tests market includes various segments, such as Hepatitis B Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests, Hepatitis B Nucleic Acid Amplification Tests (NAATs), and Multi-parameter HIV, Hepatitis B, and Hepatitis C NAATs.

Cytomegalovirus (CMV) Tests Market Report 2022: Featuring Abbott, Danaher, Bio-Rad Laboratories, Merck & More - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 2, 2023
Health, Other Health, Naʽat, Reading, Danaher Corporation, Siemens, Pregnancy, WHO model list of essential in vitro diagnostics, SWOT analysis, Abbott Laboratories, Laboratory, QuidelOrtho, Internet, SWOT, Patient, DiaSorin, CMO, CMV, Strategic planning, EIA, Market access, COVID-19, Investment, ASP, Infection, Model, Region, Immunodeficiency, Country, Retail, Health care, Risk management, Fine chemical, Pharmaceutical industry, Forecast, Cytomegalovirus

Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

Key Points: 
  • Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
  • The model discusses in detail the impact of COVID-19 on Cytomegalovirus(CMV) tests market for the year 2020 and beyond.
  • The CMV tests include Enzyme Immuno Assay (EIA) Tests, Nucleic Acid Amplification Tests (NAATs) and other CMV test kits.
  • Key Inclusions of the market model are:
    Currently marketed Cytomegalovirus(CMV) tests and evolving competitive landscape:
    Insightful review of the key industry trends.

Global Latent Tuberculosis Infection (LTBI) Testing Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 4, 2022
Health, COVID-19, Other Science, Clinical Trials, General Health, Science, Movement, Tuberculosis, Cancer, Company, Preventive healthcare, Non-functional testing, Spectroscopy, LabCorp, Prevalence, Infection, TST, Naʽat, Disulfiram-like drug, MDR-TB, CAGR, IGRA, Center, COVID-19, Institutionalisation, Ageing, Health, Immune system, Growth, LTBI, HIV, Pharmacy, Bacteria, TB, Immunosuppression, CDC, Patient, Diagnosis, Risk, Interferon, Urbanization, Cdx, Centers for Disease Control and Prevention timeline, Population, Pharmaceutical industry, Vaccine, Tobacco, Medical device, Fine chemical, Heating, ventilation, and air conditioning

The "Global Latent Tuberculosis Infection (LTBI) Testing Market: Analysis By Type (Tuberculin Skin Test LTBI Testing and Interferon Gamma Released Assay (IGRA) LTBI Testing), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Latent Tuberculosis Infection (LTBI) Testing Market: Analysis By Type (Tuberculin Skin Test LTBI Testing and Interferon Gamma Released Assay (IGRA) LTBI Testing), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global latent tuberculosis infection (LTBI) testing market in 2021 was valued at US$1.75 billion and is expected to reach US$2.47 billion by 2027, growing at a CAGR of 5.95% during 2022-2027.
  • One of the most important factors impacting the global latent tuberculosis infection (LTBI) testing market is aging population.
  • As the aging population grows further, the risk of latent tuberculosis prevalence among them also tends to increase, which is expanding the scope for the growth of the global latent tuberculosis infection testing market in coming years.

Hepatitis C Tests Market Research Report 2022: Size, Segments, Share, Trends, Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecasts, 2015-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022
Other Manufacturing, Medical Supplies, Infectious Diseases, Hospitals, Manufacturing, Other Health, Pharmaceutical, Health, Science, Other Science, Antibody, Country, World Health Organization, Risk, Conditional sentence, Microsoft Excel, ASP, Pregnancy, Liver disease, Investment, Hepatitis, Patient, Epidemiology, Review, Degenerative disease, COVID-19, Hepatitis C, Multi, SWOT, SWOT analysis, RNA, Infection, Naʽat, Region, Diagnosis, Hepatitis C virus, Hepatitis B, World, WHO, HCV, Retail, Pharmaceutical industry, Vaccine, Healthcare, Forecast

The model discusses in detail the impact of COVID-19 on Hepatitis C Tests market for the year 2020 and beyond.

Key Points: 
  • The model discusses in detail the impact of COVID-19 on Hepatitis C Tests market for the year 2020 and beyond.
  • Hepatitis C is a viral infection caused by hepatitis C virus (HCV).
  • Hepatitis C virus is a blood borne virus that causes liver disease and can cause acute and chronic hepatitis.
  • The Hepatitis C virus tests includes Hepatitis C Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests, Hepatitis C Nucleic Acid Amplification Tests (NAATs) and Multi-parameter HIV, Hepatitis B, and Hepatitis C Nucleic Acid Amplification Tests (NAATs).

Hologic Announces European CE Mark for Molecular Assays for Use with Transplant Patients

Retrieved on: 
Wednesday, May 25, 2022
Oncology, Health, FDA, Medical Devices, Infectious Diseases, Stem Cells, Surgery, Sequence, Population, International, Infection, Family, Nasdaq, Patient, Science, Antibody, Naʽat, Viral load, Society, EBV, Mortality, BK, Plasma, BKV, BK virus, NAAT, Stenosis, Immunodeficiency, Virus, Technology, Biomarker, Kidney, HOLX, PCR, Diagnosis, Polyomaviridae, Real-time polymerase chain reaction, Medical device, Vaccine, Disease, Hologic

Hologic, Inc. (Nasdaq: HOLX) announced it has received CE marking for two new molecular assays, Panther Fusion EBV Quant Assay and Panther Fusion BKV Quant Assay, expanding its transplant pathogen monitoring menu on the Panther Fusion system.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX) announced it has received CE marking for two new molecular assays, Panther Fusion EBV Quant Assay and Panther Fusion BKV Quant Assay, expanding its transplant pathogen monitoring menu on the Panther Fusion system.
  • The assays quantify the viral load of the respective viruses and are intended to aid the diagnosis and management of solid organ transplant patients and hematopoietic stem cell transplant patients.
  • Plasma, whole blood and urine specimens are important biomarkers when using quantitative NAATs for diagnosis and management of transplant patients.
  • It is crucial that viral levels are accurately quantitated in transplant recipients to guide treatment decisions and monitor response to therapy.1,2
    Immunocompromised patients are vulnerable to a range of infections.

Domus Diagnostics Announces Prototype SARS-COV-2 Diagnostic Test

Retrieved on: 
Wednesday, April 20, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, CEO, Lists of countries and territories, Gaps, COVID-19, Airport, Collection, Bacteria, Naʽat, Board of directors, PCR, World, Infection, Fungus, Duke University, Head, COVID-19 testing, Death, Electricity, Diagnosis, Professor, NAAT, FDA, World Health Organization, School, Virus, Vaccine, Pharmaceutical industry, Management, Domus

Domus Diagnostics reverse transcription loop-mediated isothermal amplification (RT-LAMP) test is intended to provide affordable, user-friendly, accurate and effective infectious disease detection to the general public.

Key Points: 
  • Domus Diagnostics reverse transcription loop-mediated isothermal amplification (RT-LAMP) test is intended to provide affordable, user-friendly, accurate and effective infectious disease detection to the general public.
  • Because the Domus platform can detect multiple targets from one sample, Domus will seek FDA authorization for a multiplex test for COVID-19 and seasonal flu after clinical trials have been completed.
  • The Domus test, which can achieve testing accuracy on par with a PCR test, doesnt require instrumentation, electricity, or cold chain logistics.
  • Domus Diagnostics goal is to produce a test that can be manufactured anywhere and sold at a price that is lower than what antigen tests are currently sold for in the US.

COVID-19 Nucleic Acid Amplification Tests (NAATs) Medical Devices Pipeline Market Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 10, 2022
Infectious Diseases, Health, Medical Devices, Naʽat, 19, PCR, Severe acute respiratory syndrome coronavirus 2, COVID, NAAT, Pharmaceutical industry, Vaccine

The "COVID-19 Nucleic Acid Amplification Tests (NAATs) - Medical Devices Pipeline Product Landscape, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "COVID-19 Nucleic Acid Amplification Tests (NAATs) - Medical Devices Pipeline Product Landscape, 2021" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information about the COVID 19 Nucleic Acid Amplification Tests (NAATs) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
  • NAAT involves amplification of specific nucleic acid sequences of SARS-CoV-2 virus by targeting specific nucleic acid sequences.
  • Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Microbix Presenting Product Results at AACC

Retrieved on: 
Monday, September 27, 2021
VOC, Infection, News, Goal, AACC, American Association, WT, Naʽat, Solution, TSX, Health, FDA, American Association for Clinical Chemistry, EQA, Engineering, Poster, TGA, Volatile organic compound, Association, Company, Product management, Medical device, Health Canada, U.S. FDA, QAP (Colombia), COVID-19, CE, Antigen, Severe acute respiratory syndrome coronavirus 2, R, Organization, ISO 9001, OTCQX, GLOBE, Vaccine, Online shopping

Results reported relate to the B.1.1.7, B.1.351, P.1, and WT variants, formerly known as the UK, South African, Brazilian, and Wuhan strains.

Key Points: 
  • Results reported relate to the B.1.1.7, B.1.351, P.1, and WT variants, formerly known as the UK, South African, Brazilian, and Wuhan strains.
  • The results demonstrate that these Microbix QAPs are compatible with over 20 widely-used COVID-19 NAATs, including those that can detect and differentiate VOCs.
  • The overall Microbix QAPs portfolio now comprises more than 70 distinct products across multiple categories of infectious diseases, test types, and test formats.
  • QAPs product enquiries can also be e-mailed directly to Microbix at [email protected] .

Microbiologics Launches SARS-CoV-2 Whole Virus Antigen Controls for Point-of-Care COVID-19 Diagnostics

Retrieved on: 
Tuesday, August 31, 2021
Cloud, Microbiology, ISO/IEC 17025, Research and development, Severe acute respiratory syndrome coronavirus 2, China Biologic Products, QC, GLOBE, Collection, IVD, Science, Health, ISO, NP, POC, Membrane protein, RUO, Safety, COVID-19 testing, Naʽat, Medical microbiology, Solution, NAAT, COVID-19, Virology, Drug development, Vaccine

Cloud, Minnesota, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Microbiologics has launched a new SARS-CoV-2 quality control (QC) product designed for use with antigen point-of-care (POC) methods.

Key Points: 
  • Cloud, Minnesota, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Microbiologics has launched a new SARS-CoV-2 quality control (QC) product designed for use with antigen point-of-care (POC) methods.
  • The inactivated SARS-CoV-2 Whole Virus Antigen Control is highly concentrated with fully intact genomic and viral proteins, making it suitable for both antigen tests and nucleic acid amplification tests (NAATs).
  • Microbiologics offers their SARS-CoV-2 Whole Virus Antigen Control in a kit containing 6 individually packaged lyophilized swabs.
  • Brad Goskowicz, Microbiologics Chief Executive Officer, commented, Creating confidence is science is ingrained in who we are at Microbiologics.